FFO
MBX

Fortitude Family Office’s MBX Biosciences MBX Stock Holding History

Fortitude Family Office’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05K Hold
19
– – ﹤0.01% 1743
2026
Q1 		$567 Buy
+19
New +$646 ﹤0.01% 1677

Other funds holding MBX

AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
KWM
Koa Wealth Management Encinitas, California $147M AUM 18.41% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
GIM
Goelzer Investment Management Carmel, Indiana $2.29B AUM 39.12% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

Fortitude Family Office's MBX Position: Q2 2026 in Review

Fortitude Family Office held its MBX Biosciences (MBX) position steady in Q2 2026 at 19 shares worth $1.05K. The position accounts for ﹤0.01% of the portfolio, ranked #1743.

Fortitude Family Office first reported a position in MBX in Q1 2026 and has held it in 2 quarters since. 16 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Fortitude Family Office held 19 shares of MBX Biosciences worth $1.05K as of Q2 2026.
  • Fortitude Family Office left its MBX Biosciences share count unchanged in Q2 2026.
  • MBX Biosciences made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1743 holding.
  • Fortitude Family Office first reported a position in MBX Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 16 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.